Bavarian Nordic, the Danish vaccine maker, has selected a new chief executive to replace longtime CEO Paul Chaplin. Chaplin's exit was announced earlier this year, and the company has now lined up a successor with senior leadership experience across several major pharmaceutical companies, including Sanofi, AstraZeneca and Pfizer.
The incoming CEO's background spans both large-cap drugmakers and the vaccine space, which could prove relevant as Bavarian Nordic continues to build on its portfolio of vaccines for infectious diseases. The move signals continuity for the company during its leadership transition.
Since the report draws on a single source, there are no differing accounts to compare. The source does not specify the new CEO's name, exact start date, or prior titles, only that the executive is a veteran of Sanofi, AstraZeneca and Pfizer.